Related references
Note: Only part of the references are listed.Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The role of IL 23 in the treatment of psoriasis
Lluis Puig
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2017)
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
Francisco J. Blanco et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D. M. Saunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis
Sophie Glatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
IL-17 and IL-22 in immunity: Driving protection and pathology
Kilian Eyerich et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
CD11c+ monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23
I. C. Arnold et al.
MUCOSAL IMMUNOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
No meaningful association between suicidal behavior and the use of
Andrea Chiricozzi et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy
Parakkal Deepak et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Interleukin-23-Dependent/T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
Annika Reinhardt et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Benjamin Farahnik et al.
DERMATOLOGY AND THERAPY (2016)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Jacob S. Lee et al.
IMMUNITY (2015)
Gut-Busters: IL-17 Ain't Afraid of No IL-23
Natasha Whibley et al.
IMMUNITY (2015)
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Joseph R. Maxwell et al.
IMMUNITY (2015)
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS
Ivette Essers et al.
RHEUMATOLOGY (2015)
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Denis Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Paradoxical effects of anti-TNF-α agents in inflammatory diseases
Daniel Wendling et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
Stanley Cheuk et al.
JOURNAL OF IMMUNOLOGY (2014)
IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells
Ryutaro Yoshiki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Charles W. Lynde et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Specific targeting of interleukin-23p19 as effective treatment for psoriasis
Adriane A. Levin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice
Christian Wohn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Briakinumab for the Treatment of Plaque Psoriasis
Pawel Traczewski et al.
BIODRUGS (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Therapeutic potential of targeting IL-17
Sarah A Jones et al.
NATURE IMMUNOLOGY (2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
B. E. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
A. B. Gottlieb et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A
Heather L. Rizzo et al.
JOURNAL OF IMMUNOLOGY (2011)
Human TH17 Cells Are Long-Lived Effector Memory Cells
Ilona Kryczek et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
P. ETTEHADI et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Psoriasis: what we have learned from mouse models
Erwin F. Wagner et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis
Angelique N. Collamer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Innate IL-17-producing cells: the sentinels of the immune system
Daniel J. Cua et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
Leslie van der Fits et al.
JOURNAL OF IMMUNOLOGY (2009)
Association of interleukin-23 receptor variants with ankylosing spondylitis
Proton Rahman et al.
ARTHRITIS AND RHEUMATISM (2008)
IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
Gretta L. Stritesky et al.
JOURNAL OF IMMUNOLOGY (2008)
Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis
Emma Guttman-Yassky et al.
JOURNAL OF IMMUNOLOGY (2008)
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis
Rajan P. Nair et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Repeated subcutaneous injections of IL12/23 P40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Benjamin M. Segal et al.
LANCET NEUROLOGY (2008)
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis
Francesca Capon et al.
HUMAN GENETICS (2007)
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Nicholas J. Wilson et al.
NATURE IMMUNOLOGY (2007)
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells
Akihiro Kimura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Stat3 and Stat4 direct development of IL-17-secreting Th cells
Anubhav N. Mathur et al.
JOURNAL OF IMMUNOLOGY (2007)
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes
Michele Cargill et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Interleukin-23 drives innate and T cell-mediated intestinal inflammation
Sophie Hue et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells
Ivaylo I. Ivanov et al.
CELL (2006)
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
G Piskin et al.
JOURNAL OF IMMUNOLOGY (2006)
IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12
MA Kleinschek et al.
JOURNAL OF IMMUNOLOGY (2006)
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
CL Langrish et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: Elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis
C Schmidt et al.
INFLAMMATORY BOWEL DISEASES (2005)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
IL-12 and IL-23: master regulators of innate and adaptive immunity
CL Langrish et al.
IMMUNOLOGICAL REVIEWS (2004)
TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin
T Biedermann et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist
S Nakae et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al.
IMMUNITY (2000)
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
PJ Mease et al.
LANCET (2000)
Share Paper
